KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Common Equity (2020 - 2025)

Recursion Pharmaceuticals' Common Equity history spans 6 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Common Equity rose 9.29% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, up 9.29%, while the annual FY2025 figure was $1.1 billion, 9.29% up from the prior year.
  • Common Equity reached $1.1 billion in Q4 2025 per RXRX's latest filing, up from $1.0 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.1 billion in Q4 2025 to a low of -$233.0 million in Q1 2021.
  • Average Common Equity over 5 years is $586.7 million, with a median of $509.1 million recorded in 2022.
  • The largest YoY upside for Common Equity was 503.11% in 2021 against a maximum downside of 64.82% in 2021.
  • A 5-year view of Common Equity shows it stood at $542.9 million in 2021, then decreased by 10.52% to $485.8 million in 2022, then fell by 4.6% to $463.4 million in 2023, then surged by 123.28% to $1.0 billion in 2024, then rose by 9.29% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Common Equity are $1.1 billion (Q4 2025), $1.0 billion (Q3 2025), and $919.1 million (Q2 2025).